Female patient, 33 years old, presenting asymptomatic swelling in the right maxilla with elevation of the nose wing, evolving from 30 days, without lymph node enlargement. Computed tomography showed an area of thickening and densification of the skin and subcutaneous tissue at the right nasolabial fold, with contrast enhancement, without a liquefied image and with poorly defined contours with approximately 3.3 cm. A histopathological examination showed fibroconnective tissue with a dense lymphomononuclear inflammatory infiltrate, which was inconclusive. A immunohistochemical study showed presence of lymphocytic infiltrate of small to medium cells with slightly irregular nuclei, with positivity for CD2, CD56, GATA-3, TIA-1 and CD3, and negativity for CD5 and CD7, and a high proliferative index for Ki67 (70-80%). Research for the Epstein-Barr virus revealed diffuse positivity in the tumor cells. The set of findings was suggestive of extranodal T/NK cell lymphoma, nasal type. The patient was referred to hematooncology team. Female patient, 33 years old, presenting asymptomatic swelling in the right maxilla with elevation of the nose wing, evolving from 30 days, without lymph node enlargement. Computed tomography showed an area of thickening and densification of the skin and subcutaneous tissue at the right nasolabial fold, with contrast enhancement, without a liquefied image and with poorly defined contours with approximately 3.3 cm. A histopathological examination showed fibroconnective tissue with a dense lymphomononuclear inflammatory infiltrate, which was inconclusive. A immunohistochemical study showed presence of lymphocytic infiltrate of small to medium cells with slightly irregular nuclei, with positivity for CD2, CD56, GATA-3, TIA-1 and CD3, and negativity for CD5 and CD7, and a high proliferative index for Ki67 (70-80%). Research for the Epstein-Barr virus revealed diffuse positivity in the tumor cells. The set of findings was suggestive of extranodal T/NK cell lymphoma, nasal type. The patient was referred to hematooncology team.